Chemotherapy Market Analysis
ID: MRFR/Pharma/4335-CR
126 Pages
February 2021
Chemotherapy Market Research Report Information By Drug Class (Mitotic Inhibitors, Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors and Antitumor Antibiotic), By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Leukemia and Ovarian Cancer), By Route of Drug Administration (Intravenous, Oral, Subcutaneous, Intra-Muscular, Intravesi...
Market Summary
As per Market Research Future Analysis, the global chemotherapy market was valued at USD 8.9 billion in 2023 and is projected to grow to USD 16.84 billion by 2032, with a CAGR of 7.40% from 2024 to 2032. Key drivers include rising cancer prevalence, increased compliance with chemotherapy drugs, and advancements in drug delivery and biologics. The market is also influenced by the growing awareness of cancer and the aging population, which is expected to boost demand for chemotherapeutic medications.
Key Market Trends & Highlights
The chemotherapy market is experiencing significant growth driven by various factors.
- Projected market growth from USD 9.6 billion in 2024 to USD 16.84 billion by 2032.
- Alkylating agents accounted for 39.7% of market revenue in 2023, totaling USD 3.3 billion.
- Leukemia was the leading indication in 2022, with rising cases of breast cancer also contributing to market expansion.
- North America is the largest regional market, driven by high healthcare spending and advanced medical facilities.
Market Size & Forecast
| 2023 Market Size | USD 8.9 Billion |
| 2024 Market Size | USD 9.6 Billion |
| 2032 Market Size | USD 16.84 Billion |
| CAGR (2024-2032) | 7.40% |
| Largest Regional Market Share in 2024 | North America. |
Major Players
Key players include Pfizer Inc. (US), Sanofi S.A. (France), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson Services Inc (US).
Market Trends
Growing cancer rates are fueling the market growth
Market CAGR for chemotherapy is driven by the rising number of cancer patients. Cancer incidence has climbed globally, overtaking cardiovascular diseases as the second greatest cause of death. This phenomenon is caused by environmental variables such as cigarette use, altered dietary habits, urbanization, and prolonged post-reproductive lifetime. For instance, the World Health Organisation (WHO) estimates that there will be 29.4 million new instances of cancer worldwide by 2040, up from 18.1 million in 2018. Therefore, it is anticipated that the rising incidence of cancer will increase the demand for oncology cancer medications globally throughout the projection period.
Furthermore, the industry will benefit from the population's growing cancer awareness in the next years.
Cancer treatment is developing more quickly than ever. Emerging from the research and development pipeline are several novel treatments frequently combined with other brand-new or current medications. Numerous pharmaceutical companies are funding these revolutionary medication development projects to treat cancer. For instance, Pfizer purchased Array BioPharma in June 2019, intending to expand its oncology footprint and pipeline, starting with a melanoma combination medication that has been licensed and is currently testing for metastatic colorectal cancer. This is expected to accelerate market expansion and grow consumer desire for biosimilar and biologic products.
Another significant element influencing the growth rate of the market for chemotherapy is the rising cost of healthcare, which contributes to the development of its infrastructure. Government organizations' efforts to upgrade the healthcare infrastructure will further impact the market dynamics by increasing funding. Another significant element influencing the growth rate of the market for chemotherapy is the rising cost of healthcare, which contributes to the development of its infrastructure. Government organizations' efforts to upgrade the healthcare infrastructure will further impact the market dynamics by increasing funding.
Rising chemo awareness and an increase in patients undergoing these treatments are further factors expected to speed up the market's growth rate. Because of aging demographics, the demand for chemotherapeutic medications will also expand. Thus, driving the chemotherapy market revenue.
The ongoing advancements in chemotherapy treatments are poised to enhance patient outcomes and expand therapeutic options, reflecting a dynamic evolution in oncology care.
U.S. National Cancer Institute
Chemotherapy Market Market Drivers
Market Growth Projections
The Global Global Chemotherapy Market Industry is projected to experience substantial growth over the coming years. The market is expected to reach a value of 9.6 USD Billion in 2024 and is anticipated to grow to 20.9 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 7.31% from 2025 to 2035. Such projections indicate a robust demand for chemotherapy treatments, driven by various factors including advancements in drug development, increasing cancer incidence, and enhanced healthcare access. These figures underscore the market's potential and the critical need for continued investment in cancer therapies.
Rising Incidence of Cancer
The Global Global Chemotherapy Market Industry is experiencing growth driven by the increasing incidence of cancer worldwide. According to data from the World Health Organization, cancer cases are projected to rise significantly, with an estimated 19.3 million new cases diagnosed in 2020. This alarming trend necessitates the development and administration of effective chemotherapy treatments, thereby propelling market expansion. As the global population ages and lifestyle factors contribute to higher cancer rates, the demand for chemotherapy is expected to surge, contributing to the market's projected value of 9.6 USD Billion in 2024.
Increased Healthcare Expenditure
Rising healthcare expenditure globally is a significant factor influencing the Global Global Chemotherapy Market Industry. Governments and private sectors are investing more in healthcare infrastructure and cancer treatment programs. According to the World Bank, global health expenditure has been on an upward trajectory, with many countries allocating larger budgets to oncology services. This increased funding facilitates access to chemotherapy treatments, thereby expanding the market. As healthcare systems evolve and prioritize cancer care, the Global Global Chemotherapy Market is likely to witness sustained growth, with a projected CAGR of 7.31% from 2025 to 2035.
Advancements in Chemotherapy Drugs
Innovations in chemotherapy drugs are a pivotal driver for the Global Global Chemotherapy Market Industry. The introduction of targeted therapies and immunotherapies has transformed treatment protocols, offering more effective options with fewer side effects. For instance, the development of monoclonal antibodies and small molecule inhibitors has enhanced treatment efficacy for various cancers. These advancements not only improve patient outcomes but also stimulate market growth, as healthcare providers increasingly adopt these novel therapies. The market is anticipated to reach 20.9 USD Billion by 2035, reflecting the impact of these innovations on chemotherapy practices.
Emerging Markets and Accessibility
Emerging markets are becoming increasingly relevant to the Global Global Chemotherapy Market Industry. Countries in Asia, Africa, and Latin America are witnessing improvements in healthcare access and infrastructure, leading to greater availability of chemotherapy treatments. For instance, initiatives to enhance healthcare systems in India and Brazil have resulted in increased patient access to essential cancer therapies. This trend is likely to contribute to market growth as more patients seek treatment. The Global Global Chemotherapy Market is poised for expansion, with emerging economies playing a crucial role in shaping future demand.
Growing Awareness and Screening Programs
The Global Global Chemotherapy Market Industry benefits from heightened awareness of cancer and the importance of early detection. Public health campaigns and screening programs have been instrumental in educating populations about cancer risks and the necessity for timely treatment. For example, initiatives led by the American Cancer Society have significantly increased screening rates, leading to earlier diagnoses. This proactive approach not only improves survival rates but also drives demand for chemotherapy as a treatment option. As awareness continues to grow, the market is expected to expand, reflecting the critical role of education in cancer management.
Market Segment Insights
Chemotherapy Drug Class Insights
The chemotherapy market segmentation, based on drug class, includes mitotic inhibitors, alkylating agents, antimetabolites, topoisomerase inhibitors and antitumor antibiotics. The alkylating agent segment dominated the market, accounting for 39.7% of market revenue (3.3 Billion). Alkylating substances result in DNA strand breakage, odd base pairing, or cross-linking of DNA strands, which prevents cell division. Generally speaking, alkylating chemicals are considered cell cycle phase nonspecific, meaning they can kill cells at different points in the cell cycle. The market for anti-metabolite drugs will expand dramatically as cancer rates increase globally.
The anti-metabolite medication sector will also grow due to increased pipeline research and rising healthcare costs.
Figure 2: Chemotherapy Market by Drug Class, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review
Chemotherapy Indication Insights
The chemotherapy market segmentation, based on indication, includes breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, lymphoma, leukemia and ovarian cancer. In 2022, leukemia dominated the market. Leukaemias with a sluggish growth rate may require monitoring as part of their treatment. Radiation therapy, stem cell transplant, and chemotherapy are sometimes used together to treat severe leukemias. Furthermore, the cases of breast cancer are also rising at a significant rate. The sector's growth is driven by the increasing prevalence of breast cancer in women, the variety of therapies available, and improved methods for breast cancer diagnostics using cutting-edge technologies.
Chemotherapy Route of Drug Administration Insights
The chemotherapy market segmentation, based on the route of drug administration, includes intravenous, oral, subcutaneous, intra-muscular, intravesicular, topical, intraperitoneal and intraventricular/intrathecal. The market's largest contributor, the oral category, is anticipated to expand at a major rate over the projected period. An oral cancer treatment drug is available as a pill, capsule, or liquid. However, the intravenous route witnessed the fastest growth rate. Since they are administered intravenously, chemotherapy drugs function more quickly than oral and topical treatments because they are instantly absorbed into the bloodstream.
Chemotherapy End-User Insights
The chemotherapy market segmentation, based on end-user, includes specialty centers and hospitals & clinics. The hospitals & clinics segment, dominated the market throughout the projected period. The precise cancer treatment provided in hospitals, the presence of qualified medical personnel, the availability of cutting-edge medical equipment, and favorable reimbursement rules are all associated with the sub-segments rapid rise. In 2022, specialty centers saw the fastest growth rate. Specialist centers are expected to be created due to several causes, including the rise in chronic illness cases, the expansion of public-private partnerships in the healthcare sector, and the growing senior population.
Get more detailed insights about Chemotherapy Market Research Report -Forecast till 2032
Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American chemotherapy market area will dominate this market. Multiple manufacturers of chemotherapy drugs and increased healthcare spending are North America's main market drivers. Accessibility to medical facilities and the application of cutting-edge technology in the study and treatment of cancer are other factors driving the market.
Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.
Figure 2: CHEMOTHERAPY MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review
Europe’s chemotherapy market accounts for the second-largest market share. The main drivers influencing the market's growth are the ease of regulatory approval for novel cancer therapies in Europe, the rising incidence of cancer, and significant R&D spending by the major companies in the market. According to data from 2021 provided by the International Agency for the Research on Cancer, there were 4.79 million cancer cases in the European region in 2020, and that number is projected to rise to 6.07 million by 2040.
Further, the German chemotherapy market held the largest market share, and the UK chemotherapy market was the fastest-growing market in the European region
The Asia-Pacific Chemotherapy Market is estimated to expand at a rapid rate from 2024 to 2032. It results from expanded government awareness initiatives and rising healthcare costs in this area. Due to the availability of trained and qualified healthcare providers and the rising need for chemotherapy drugs, the expanding accessibility of generic medications will also help to slow the market's rate of progress in this sector. Moreover, China’s chemotherapy market held the largest market share, and the Indian chemotherapy market was the fastest-growing market in the Asia-Pacific region.
Key Players and Competitive Insights
Leading market players are largely investing in R&D to expand their production capacities, which will aid in the further expansion of the chemotherapy industry. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The chemotherapy industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.
One of the major business strategies manufacturers use in the chemotherapy industry to increase the market sector and benefit customers is local manufacturing to lower operational costs. Recently, the chemotherapy industry has stipulated some of the most important medicinal benefits. Major players in the chemotherapy market, including Pfizer Inc. (US), Sanofi S.A. (France), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson Services Inc (US), and others, are funding operations for research and development to boost market demand.
Gland Pharma, founded in 1978 in Hyderabad, India, has evolved from a contract manufacturer [HK1] of small volume liquid parenteral products to one of the world's largest and fastest growing generic injectables manufacturing companies, with a footprint spanning 60 countries, including the Europe, United States, Canada, Australia, India, and other markets. In May 2022, Gland Pharma, in collaboration with a partner, released Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial in the US market. It is bioequivalent and therapeutically equivalent to Takeda Pharmaceuticals U.S.A., Inc.'s reference listed drug (RLD), Velcade for Injection, 3.5 mg/vial.
AstraZeneca was created in 1999 by merging Astra of Sweden and Zeneca Group of the United Kingdom. The company sells branded medications in various therapeutic areas, including gastrointestinal, diabetic, cardiovascular, respiratory, cancer, immunology, and rare disorders. Most sales are done in foreign markets, with the United States making up nearly one-third of the total. In July 2021, AstraZeneca announced that the National Medical Products Administration (NMPA) had approved Imfinzi (durvalumab) for marketing in China for the medical management of patients with Stage III unresectable non-small cell lung cancer whose cancer did not advance following concurrent platinum-based chemotherapy and radiation therapy.
Key Companies in the Chemotherapy Market market include
Industry Developments
August 2022:Ipsen announced the completion of the definitive merger agreement that would see Ipsen acquire Epizyme, Inc. (Epizyme). Tazverik (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor awarded Accelerated Approval by US Food and Drug Administration in 2020, is acquired by Ipsen as part of the agreement.
September 2020:Gilead Sciences Inc announced a $21 billion acquisition of Immunomedics Inc, boosting its cancer portfolio by obtaining access to a promising medicine. The agreement grants Gilead access to Immunomedics' breast cancer treatment medicine Trodelvy, which received fast FDA approval in April for an aggressive and difficult-to-treat kind of breast cancer.
Future Outlook
Chemotherapy Market Future Outlook
The Global Chemotherapy Market is projected to grow at a 7.31% CAGR from 2024 to 2035, driven by advancements in drug development, increasing cancer prevalence, and enhanced healthcare infrastructure.
New opportunities lie in:
- Invest in personalized medicine to tailor chemotherapy treatments for individual genetic profiles.
- Develop combination therapies that enhance efficacy and reduce side effects for patients.
- Expand access to chemotherapy in emerging markets through strategic partnerships with local healthcare providers.
By 2035, the Global Chemotherapy Market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient access.
Market Segmentation
Chemotherapy Regional Outlook
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Chemotherapy Drug Class Outlook
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Chemotherapy Indication Outlook
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Chemotherapy End-User Outlook
- Specialty Centers
- Hospitals & Clinics
Chemotherapy Route of Drug Administration Outlook
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Report Scope
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 8.9 Billion |
| Market Size 2024 | USD 9.55 Billion |
| Market Size 2032 | USD 16.84 Billion |
| Compound Annual Growth Rate (CAGR) | 7.4% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Market Competitive Landscape, Growth Factors, Revenue Forecast, and Trends |
| Segments Covered | Drug Class, Route of Drug Administration, Indication, and End-User |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil. |
| Key Companies Profiled | Pfizer Inc. (US), Sanofi S.A. (France), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson Services Inc (US). |
| Key Market Opportunities | Entering developing economies |
| Key Market Dynamics | Increasing prevalence of cancer |
Market Highlights
Author
Latest Comments
John Doe
This is a great article! Really helped me understand the topic better.
Posted on July 23, 2025, 10:15
AM
Jane Smith
Thanks for sharing this. I’ve bookmarked it for later reference.
Posted on July 22, 2025, 7:45
PM
FAQs
How much is the chemotherapy market?
The market size of the chemotherapy market was prized at USD 8.9 Billion in 2023.
What is the growth rate of the chemotherapy market?
From 2024 to 2032, the anticipated CAGR for the market is 7.4%.
Which region held the major market share in the chemotherapy market?
The major portion of the market was accounted for by North America.
Who are the notable players in the chemotherapy market?
The notable players in the market are Pfizer Inc. (US), Sanofi S.A. (France), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson Services Inc (US).
Which drug class led the chemotherapy market?
The alkylating agents dominated the market in 2022.
Which indication had the major market share in the chemotherapy market?
The leukemia sector had the largest share of the market.
-
Increasing Expenditure on Oncology Medicine and Research
- Reimbursements
-
and Growing Health Insurance
-
Restraints
- High Cost of Treatment
- Side-Effects of Chemotherapy
- Opportunities
-
Restraints
-
Entering Developing Economies
-
Value Chain Analysis
- R&D and Designing
- Manufacturing
-
Value Chain Analysis
-
Distribution & Sales
- Post-Sales Review
- Porter’s
-
Five Forces Model
-
Bargaining Power of Suppliers
- Bargaining
-
Bargaining Power of Suppliers
-
Power of Buyers
-
Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
- Investment Opportunities Analysis
- Pricing Analysis
- Chemotherapy Drugs by Route of Administration
- Chemotherapy Drugs by Indication
- Introduction
- Alkylating agents
- Mitotic inhibitors
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor antibiotic
- Introduction
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
-
Threat of New Entrants
-
Market, by Route of Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
-
Chemotherapy Market, by End User
- Introduction
- Specialty Centers
- Hospitals & Clinics
- Introduction
-
Americas
- North America
- South America
-
Europe
- Western Europe
- Eastern Europe
-
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
-
Middle East & Africa
- Middle East
- Africa
- Company Share Analysis
-
Johnson & Johnson Services Inc.
- Company Overview
- Financial Overview
- Products/Services Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
GlaxoSmithKline PLC
- Company Overview
- Financial Overview
- Products/Services Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Eli Lilly and Company
- Company Overview
- Financial Overview
- Products/Services Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
F. Hoffmann-La Roche Ltd
- Company Overview
- Financial Overview
- Products/Services Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Novartis AG
- Company Overview
- Financial Overview
- Products/Services Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Pfizer Inc.
- Company Overview
- Financial Overview
- Products/Services Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Merck & Co. Inc.
- Company Overview
- Financial Overview
- Products/Services Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Sanofi S.A.
- Company Overview
- Financial Overview
- Products/Services Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Celgene Corporation
- Company Overview
- Financial Overview
- Products/Services Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Bristol-Myers Squibb Company
- Company Overview
- Financial Overview
- Products/Services Offered
- Key Developments
- SWOT Analysis
- Key Strategies
- References
- Related Reports
-
(USD MILLION)
-
BY REGION, 2020–2027 (USD MILLION)
-
FOR ANTIMETABOLITES, BY REGION, 2020–2027 (USD MILLION)
-
CHEMOTHERAPY MARKET FOR TOPOISOMERASE INHIBITORS, BY REGION, 2020–2027 (USD MILLION)
-
REGION, 2020–2027 (USD MILLION)
-
BY INDICATION, 2020–2027 (USD MILLION)
-
MARKET FOR LUNG CANCER, BY REGION, 2020–2027 (USD MILLION)
-
GLOBAL CHEMOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION)
-
REGION, 2020–2027 (USD MILLION)
-
FOR STOMACH CANCER, BY REGION, 2020–2027 (USD MILLION)
-
CHEMOTHERAPY MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
-
MILLION)
-
2020–2027 (USD MILLION)
-
OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
MARKET FOR INTRAVENOUS, BY REGION, 2020–2027 (USD MILLION)
-
GLOBAL CHEMOTHERAPY MARKET FOR ORAL, BY REGION, 2020–2027 (USD MILLION)
-
(USD MILLION)
-
REGION, 2020–2027 (USD MILLION)
-
FOR INTRAVESICULAR, BY REGION, 2020–2027 (USD MILLION)
-
CHEMOTHERAPY MARKET FOR TOPICAL, BY REGION, 2020–2027 (USD MILLION)
-
(USD MILLION)
-
BY REGION, 2020–2027 (USD MILLION)
-
BY END USER, 2020–2027 (USD MILLION)
-
MARKET FOR SPECIALITY CENTERS, BY REGION, 2020–2027 (USD MILLION)
-
(USD MILLION)
-
(USD MILLION)
-
(USD MILLION)
-
(USD MILLION)
-
2020–2027 (USD MILLION)
-
END USER, 2020–2027 (USD MILLION)
-
MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
-
CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
-
2020–2027 (USD MILLION)
-
BY END USER, 2020–2027 (USD MILLION)
-
BY DRUG CLASS, 2020–2027 (USD MILLION)
-
BY INDICATION, 2020–2027 (USD MILLION)
-
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
MARKET, BY END USER, 2020–2027 (USD MILLION)
-
MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
-
MARKET, BY INDICATION, 2020–2027 (USD MILLION)
-
MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
MILLION)
-
(USD MILLION)
-
2020–2027 (USD MILLION)
-
BY END USER, 2020–2027 (USD MILLION)
-
MARKET, BY REGION, 2020–2027 (USD MILLION)
-
MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
-
MARKET, BY INDICATION, 2020–2027 (USD MILLION)
-
MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
MILLION)
-
(USD MILLION)
-
2020–2027 (USD MILLION)
-
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
EUROPE: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION)
-
(USD MILLION)
-
(USD MILLION)
-
(USD MILLION)
-
2020–2027 (USD MILLION)
-
USER, 2020–2027 (USD MILLION)
-
DRUG CLASS, 2020–2027 (USD MILLION)
-
BY INDICATION, 2020–2027 (USD MILLION)
-
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
MARKET, BY END USER, 2020–2027 (USD MILLION)
-
MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
-
MARKET, BY INDICATION, 2020–2027 (USD MILLION)
-
MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
2020–2027 (USD MILLION)
-
USER, 2020–2027 (USD MILLION)
-
MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
-
EUROPE: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
-
2020–2027 (USD MILLION)
-
MARKET, BY END USER, 2020–2027 (USD MILLION)
-
CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
-
2020–2027 (USD MILLION)
-
BY END USER, 2020–2027 (USD MILLION)
-
MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
-
CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
-
2020–2027 (USD MILLION)
-
BY END USER, 2020–2027 (USD MILLION)
-
MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
-
MARKET, BY INDICATION, 2020–2027 (USD MILLION)
-
MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
2020–2027 (USD MILLION)
-
USER, 2020–2027 (USD MILLION)
-
BY DRUG CLASS, 2020–2027 (USD MILLION)
-
MARKET, BY INDICATION, 2020–2027 (USD MILLION)
-
MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
MILLION)
-
(USD MILLION)
-
2020–2027 (USD MILLION)
-
BY END USER, 2020–2027 (USD MILLION)
-
MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
-
CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
-
(USD MILLION)
-
CLASS, 2020–2027 (USD MILLION)
-
MARKET, BY INDICATION, 2020–2027 (USD MILLION)
-
CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
(USD MILLION)
-
REGION, 2020–2027 (USD MILLION)
-
CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
-
ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
EAST & AFRICA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION)
-
2020–2027 (USD MILLION)
-
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
-
EAST: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION)
-
(USD MILLION)
-
& BOTTOM-UP APPROACH
-
CHEMOTHERAPY MARKET
-
2020 & 2027 (USD MILLION)
-
USER, 2020 & 2027 (USD MILLION)
-
BY REGION, 2020 & 2027 (USD MILLION)
-
MARKET SHARE, BY REGION, 2020 (%)
-
MARKET SHARE, BY COUNTRY, 2020 (%)
-
SHARE, BY REGION, 2020 (%)
-
SHARE, BY COUNTRY, 2020 (%)
-
SHARE, BY COUNTRY, 2020 (%)
-
MARKET SHARE, BY REGION, 2020 (%)
-
COMPANY SHARE ANALYSIS, 2020
Market Segmentation
Chemotherapy Drug Class Outlook (USD Billion, 2018-2032)
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Chemotherapy Indication Outlook (USD Billion, 2018-2032)
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Chemotherapy Route of Drug Administration Outlook (USD Billion, 2018-2032)
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Chemotherapy End-User Outlook (USD Billion, 2018-2032)
- Specialty Centers
- Hospitals & Clinics
Chemotherapy Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
North America Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
North America Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
North America Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
North America Chemotherapy by End-User
Specialty Centers
- Hospitals & Clinics
US Outlook (USD Billion, 2018-2032)
US Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
US Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
US Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
US Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
CANADA Outlook (USD Billion, 2018-2032)
CANADA Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
CANADA Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
CANADA Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
CANADA Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Europe Outlook (USD Billion, 2018-2032)
Europe Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Europe Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Europe Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Europe Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Germany Outlook (USD Billion, 2018-2032)
Germany Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Germany Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Germany Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Germany Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
France Outlook (USD Billion, 2018-2032)
France Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
France Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
France Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
France Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
UK Outlook (USD Billion, 2018-2032)
UK Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
UK Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
UK Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
UK Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
ITALY Outlook (USD Billion, 2018-2032)
ITALY Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
ITALY Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
ITALY Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
ITALY Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
SPAIN Outlook (USD Billion, 2018-2032)
SPAIN Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
SPAIN Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
SPAIN Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
SPAIN Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Rest Of Europe Outlook (USD Billion, 2018-2032)
Rest Of Europe Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Rest Of Europe Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Rest Of Europe Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Rest Of Europe Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Asia-Pacific Outlook (USD Billion, 2018-2032)
Asia-Pacific Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Asia-Pacific Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Asia-Pacific Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Asia-Pacific Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
China Outlook (USD Billion, 2018-2032)
China Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
China Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
China Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
China Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Japan Outlook (USD Billion, 2018-2032)
Japan Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Japan Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Japan Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Japan Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
India Outlook (USD Billion, 2018-2032)
India Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
India Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
India Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
India Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Australia Outlook (USD Billion, 2018-2032)
Australia Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Australia Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Australia Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Australia Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
Rest of Asia-Pacific Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Rest of Asia-Pacific Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Rest of Asia-Pacific Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Rest of Asia-Pacific Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Rest of the World Outlook (USD Billion, 2018-2032)
Rest of the World Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Rest of the World Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Rest of the World Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Rest of the World Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Middle East Outlook (USD Billion, 2018-2032)
Middle East Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Middle East Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Middle East Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Middle East Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Africa Outlook (USD Billion, 2018-2032)
Africa Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Africa Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Africa Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Africa Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Latin America Outlook (USD Billion, 2018-2032)
Latin America Chemotherapy by Drug Class
- Mitotic Inhibitors
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- Antitumor Antibiotic
Latin America Chemotherapy by Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Lymphoma
- Leukemia
- Ovarian Cancer
Latin America Chemotherapy by Route of Drug Administration
- Intravenous
- Oral
- Subcutaneous
- Intra-Muscular
- Intravesicular
- Topical
- Intraperitoneal
- Intraventricular/Intrathecal
Latin America Chemotherapy by End-User
- Specialty Centers
- Hospitals & Clinics
Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment